Dr. Reddy's Laboratories Limited
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical pr… Read more
Dr. Reddy's Laboratories Limited (RDDA) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.043x
Based on the latest financial reports, Dr. Reddy's Laboratories Limited (RDDA) has a cash flow conversion efficiency ratio of 0.043x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€15.57 Billion) by net assets (€362.08 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Dr. Reddy's Laboratories Limited - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Dr. Reddy's Laboratories Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Dr. Reddy's Laboratories Limited Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Dr. Reddy's Laboratories Limited ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Daqin Railway Co Ltd
SHG:601006
|
0.021x |
|
Element Solutions Inc
NYSE:ESI
|
0.038x |
|
STORA ENSO OYJ R (RE-REG)
F:ENUN
|
N/A |
|
OBIC Co.Ltd
F:OBL
|
0.042x |
|
Semtech Corporation
NASDAQ:SMTC
|
0.072x |
|
Bankinter S.A
PINK:BKIMF
|
0.006x |
|
STORA ENSO OYJ A EO 170
F:ENUA
|
N/A |
|
EPAM Systems Inc
NYSE:EPAM
|
0.079x |
Annual Cash Flow Conversion Efficiency for Dr. Reddy's Laboratories Limited (2017–2025)
The table below shows the annual cash flow conversion efficiency of Dr. Reddy's Laboratories Limited from 2017 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | €337.17 Billion | €46.43 Billion | 0.138x | -14.97% |
| 2024-03-31 | €280.55 Billion | €45.43 Billion | 0.162x | -35.95% |
| 2023-03-31 | €232.86 Billion | €58.88 Billion | 0.253x | +71.38% |
| 2022-03-31 | €190.53 Billion | €28.11 Billion | 0.148x | -27.70% |
| 2021-03-31 | €174.98 Billion | €35.70 Billion | 0.204x | +5.97% |
| 2020-03-31 | €154.99 Billion | €29.84 Billion | 0.193x | -5.96% |
| 2019-03-31 | €140.20 Billion | €28.70 Billion | 0.205x | +43.61% |
| 2018-03-31 | €126.46 Billion | €18.03 Billion | 0.143x | -17.80% |
| 2017-03-31 | €124.04 Billion | €21.51 Billion | 0.173x | -- |